利记·sbobet(中国)-唯一官方网站

R&D Pipeline

Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.

Major Drugs under Development

As of December 2023, Fosun Pharma has 70+ major innovative drugs and biosimilars under development (calculated by indication).

  • 20
    Self-developed small molecule innovator drug
  • 25
    Self-developed innovative biologics
  • 20
    In-licensing innovator drugs
  • 10
    Self-developed biosimilars